Search
Tilactase
go.drugbank.com/drugs/DB13761ApprovedInvestigationalTilactase is a beta-D-galactosidase obtained from _Aspergillus oryzae_. It is produced as a chewable tablet that has to be taken before the consumption of a lactose-containing meal. … [A27172] The beta-D-galactosidase us a large monomeric multi-domain enzyme of 985 residues that presents a catalytic (alpha/beta)8-barrel domain.
Products: Lactase Enzyme Tablets 3300 Lac Units, LACDIGEST 2250 U CIGNEME TABLETI, 100 TABLETAmbrisentan
go.drugbank.com/drugs/DB06403ApprovedInvestigationalAmbrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. … It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: AMBRISEN 1A PHARMA 5MG, AMBRISENTAN AL 5MG FTASelenium
go.drugbank.com/drugs/DB11135ApprovedInvestigationalVet approvedSelenium is a trace metal in the human body particularly important as a component of glutathione peroxidase, an important enzyme in the prevention of cellular damage by free radicals and reactive oxygen
Mixtures: . & Selenium 50 Mcg Capsules, One A Day Advance Adults 50+Categories: Compounds used in a research, industrial, or household settingChloroquine
go.drugbank.com/drugs/DB00608ApprovedInvestigationalVet approved[A192432] **The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020. … [A191787] Chloroquine and its derivative [hydroxychloroquine] have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: OROQUİNE 250 MG/5 ML IV İNFÜZYONLUK ÇÖZELTİ , 10 ADET, KUTLU 250 MG FİLM KAPLI TABLET, 10 ADETOrphenadrine
go.drugbank.com/drugs/DB01173ApprovedInvestigationalA muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
Mixtures: Norgesic 35 mg/450 mg Tabletten, MYOGESIC-GCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsIsavuconazole
go.drugbank.com/drugs/DB11633ApprovedInvestigationalIt is proposed that the intravenous and oral dosing can be used interchangeably [L1482], without the need for a repeat loading dose when transitioning from an IV to an oral formulation [A32026]. … intravenous formulation is cyclodextrin-free which gives isavuconazole an advantage over other azole antifungals that requires cyclodextrin for facilitating drug solubility; this is because cyclodextrin has a
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesProducts: CRESEMBA (100 MG HARD CAPSULES), CRESEMBA (POWDER FOR SOLUTION FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 MG/VIAL)Ramucirumab
go.drugbank.com/drugs/DB05578ApprovedInvestigationalRamucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. … VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target.
Products: CYRAMZA 500 MG/50 ML İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇEREN FLAKON, 1 ADET, CYRAMZA 100MG/10 ML INFÜZYONLUK ÇÖZELTI KONSANTRESI IÇEREN FLAKON, 1 ADETHydrocortisone succinate
go.drugbank.com/drugs/DB14545ApprovedInvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InducersProducts: SOLU-CORTEF FOR INJECTION 100 mg/vial, SOLU-CORTEF® 100 MG POLVO PARA INYECCIONNicotinamide
go.drugbank.com/drugs/DB02701ApprovedInvestigationalAn important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra.
Mixtures: SANASOL 150 ML SURUP, HİSTOGENOL VİTAMİN ŞURUP, 150 MLCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsFinerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigationalFinerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesProducts: KERENDİA 10 MG FİLM KAPLI TABLET, 98 ADET, KERENDİA 10 MG FİLM KAPLI TABLET, 28 ADET